ELPW: Elong Power’s Energy-Storage Agreement Still Needs Execution
Elong Power announced a three-year energy-storage cooperation agreement with anticipated procurement of at least RMB 2 billion. Actual orders remain the next test.
Read the story
LABT: Lakewood-Amedex Removes a Source of Potential Dilution
Lakewood-Amedex redeemed its remaining Series C convertible preferred shares. The financing change removes one source of potential dilution, but uses cash.
Four Stocks Surging Today: Why LABT, ELPW, AMTX and DNUT Are on the Move
LABT, ELPW, AMTX and DNUT jumped after financing, energy-storage and earnings news. Here’s what investors should know about the announcements and risks.
Penny StocksEOSE: Revenue Growth Faces the Gross-Margin Test Ahead of November 5 Earnings
Eos’s preliminary sales growth supports the manufacturing-ramp story, but deeply negative gross margins remain the key financial test.
Penny StocksOCGN: Clinical Milestones and Cash Runway Put the Pipeline Ahead of the Earnings Headline
Ocugen’s November 4 update advances the clinical story, but its narrower net loss includes a large derivative-liability gain.
Penny StocksHPAI: A 300-Unit AI Deployment Target Meets a Late-Filing Warning
Helport’s autonomous-AI expansion offers a growth narrative, while its late-filing notice warns of falling revenue and a net loss.
Penny StocksXMAX: A $30 Million Buyback Authorization Meets a Weaker Sales Picture
XMax authorized purchases below $5.50 per share, but the program is conditional and preliminary results show declining sales and a loss.
Penny StocksCMTG: Loan Resolutions and Lower Debt Put a Troubled Mortgage Portfolio in Focus
Claros resolved $409.5 million of loans and reduced financing, but losses and troubled-property exposure remain central to the story.
Penny StocksSTIM: Revenue Growth and Positive Adjusted EBITDA Give the Rally Substance
Neuronetics reported stronger third-quarter sales and positive adjusted EBITDA, while a GAAP loss and cash needs keep the turnaround unfinished.
Penny StocksIMNN: ThermoDox Deal Gives a Written-Off Asset a New Path
IMUNON’s proposed ThermoDox sale offers contingent future value while management focuses on its Phase 3 ovarian-cancer program.
Penny StocksKTTA: Pasithea Approaches Its October 23 Cancer-Data Presentation
An upcoming ESMO presentation gives Pasithea a defined clinical event as its shares rebound. The actual data will matter more than anticipation.
Penny StocksSHFS: Nasdaq Gives Safe Harbor More Time as Shares Rebound
A new compliance deadline gives Safe Harbor breathing room. Restoring its bid price and strengthening the business remain separate challenges.